Pre-made Alacizumab benchmark antibody ( di-Fab, anti-KDR therapeutic antibody, Anti-FLK1/CD309/VEGFR/VEGFR2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-014-1mg	1mg	Inquiry
GMP-Bios-ab-014-10mg	10mg	Inquiry
GMP-Bios-ab-014-100mg	100mg	Inquiry
GMP-Bios-ab-014-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody
INN Name	Alacizumab
Target	KDR
Format	di-Fab
Derivation
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2007
Year Recommended	2008
Companies	UCB
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Non-small cell lung cancer
Development Tech	na